| IBIO INC. DL -,001 |
| USA |
| Gesundheit |
| US4510337086 / A3E2GR |
| 0JV0 (Frankfurt) |
| FRA:0JV0, ETR:0JV0, 0JV0:GR |
| - |
| https://ibioinc.com/ |
|
iBio Inc. is a preclinical-stage biotechnology company developing next-generation biopharmaceuticals by leveraging artificial intelligence and advanced computational biology. The company focuses on creating novel antibody-based therapies for cardiome..
>Volltext.. |
| 76.17 Mio. EUR |
| 12.67 Mio. EUR |
| 0.26 Mio. EUR |
| -20.06 Mio. EUR |
| -24.19 Mio. EUR |
| -0.51 EUR |
| 2.04 Mio. EUR |
| 41.73 Mio. EUR |
| -18.93 Mio. EUR |
| 11.5 |
| -20% |
| -31.51% |
| - |
| - |
| - |
| - |
| IBIO |
| 01.07.26 |
|